Answers are grounded in this paper and cite their sources.
Background The mechanistic target of rapamycin (mTOR) pathway plays a critical role in epileptogenesis; however, its involvement in human status epilepticus (SE) remains poorly understood. mTORopathies, genetic disorders defined by mutations that disrupt mTOR signaling, frequently manifest severe neurological complications, among which SE is particularly consequential. Methods A systematic search of PubMed, Embase, and Web of Science was conducted for studies on mTORopathies and SE. We analyzed the clinical presentation, treatment strategies, and outcomes of all cases. Results Eight hundred ninety-seven records were initially identified, of which 31 were included in this review. SE may manifest in different mTORopathies. SE often presents early, recurs frequently, and can be catastrophic. Refractory SE (RSE) predominantly affects neonates and infants and frequently occurs in the context of MCD. SE can be terminated with multiple anti-seizure medications (ASMs), alone or in combination with mTOR inhibitors. However, managing RSE is challenging. Current treatment strategies include novel ASMs, anesthetics, mTOR inhibitors, the ketogenic diet, immunotherapy, epilepsy surgery, and neuromodulation. A multifaceted approach is preferred to achieve seizure control and to improve developmental outcomes. Conclusions SE remains a significant clinical challenge in patients with mTORopathies. mTOR signaling may contribute to the pathogenesis of SE and could represent a potential therapeutic target. Further investigation in large cohort studies is needed to clarify the role of mTOR signaling in SE and to evaluate the effects of mTOR inhibitors and immunotherapies on outcomes in patients with SE/RSE.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: